Thursday, January 07, 2021 12:55:34 PM
The difference is with this being an OTC you have speculative inpatient "traders" involved with the RLFTF public float.
A "investor" looks at the company, its products and says "This looks pretty good and will be worth significantly more than I paid for it at some point"... such is the case with RLFTF.
Obsessing over RLFTF daily price, L2 info and "No PR in a week" will drive you mad and is NOT what an investor does. It has been a interesting learning experience for me to even see this first hand, 6 months of holding a ticker is just a "blip" of time in my opinion.
Nothing has changed other than a steady stream of positive news. I havent heard any negative news... The pace of which has increased as well. Ignore the daily noise, you did your DD -- your investment will take care of itself. Enjoy time with friends and family ... Be a investor
Best,
JB
A "investor" looks at the company, its products and says "This looks pretty good and will be worth significantly more than I paid for it at some point"... such is the case with RLFTF.
Obsessing over RLFTF daily price, L2 info and "No PR in a week" will drive you mad and is NOT what an investor does. It has been a interesting learning experience for me to even see this first hand, 6 months of holding a ticker is just a "blip" of time in my opinion.
Nothing has changed other than a steady stream of positive news. I havent heard any negative news... The pace of which has increased as well. Ignore the daily noise, you did your DD -- your investment will take care of itself. Enjoy time with friends and family ... Be a investor
Best,
JB
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
